From GlobeNewswire: 2024-12-04 08:01:00

The Biopharmaceutical Excipients Market was valued at USD 2.57 billion in 2023 and is projected to reach USD 4.04 billion by 2032, with a CAGR of 5.18%. The growth is driven by the demand for biologic drugs like monoclonal antibodies, vaccines, and gene therapies, requiring specific excipients for stability and bioavailability.

Excipients play a vital role in enhancing the effectiveness of biologic drugs, especially in treating chronic diseases like cancers and autoimmune disorders. The demand for specialized excipients is increasing due to the high usage of biologics, which rely on proteins and genetics for targeted disease treatment.

Advancements in pharmaceutical technology are driving the demand for special excipients, particularly in RNA-based therapies like mRNA vaccines. Major players in the market include Merck KGaA, BASF SE, and Roquette Frères, among others.

Solubilizers and surfactants/emulsifiers dominated the market in 2023, accounting for 42.0% of the market share. Injectable formulations held the largest share, while topical formulations are the fastest-growing segment.

North America led the market in 2023, driven by the adoption of biologic therapies. The Asia Pacific region is expected to experience the highest growth due to increasing healthcare expenditure and pharmaceutical manufacturing activities.

In July 2023, Roquette acquired Qualicaps to enhance its capabilities in developing pharmaceutical excipients. Roquette strengthens its market position through an acquisition, focusing on excipients for capsule formulations. Lubrizol Corporation partners with Welton Pharma to develop a new SN-38 formulation for colorectal and gastrointestinal cancers. Evonik Industries AG begins construction of a facility in Indiana to enhance the global supply chain for functional excipients, particularly for RNA medicines.



Read more at GlobeNewswire: Biopharmaceutical Excipients Market to Reach USD 4.04